Alison J. Moskowitz

9.8k total citations
194 papers, 4.1k citations indexed

About

Alison J. Moskowitz is a scholar working on Pathology and Forensic Medicine, Oncology and Dermatology. According to data from OpenAlex, Alison J. Moskowitz has authored 194 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Pathology and Forensic Medicine, 90 papers in Oncology and 54 papers in Dermatology. Recurrent topics in Alison J. Moskowitz's work include Lymphoma Diagnosis and Treatment (157 papers), Cutaneous lymphoproliferative disorders research (53 papers) and CAR-T cell therapy research (42 papers). Alison J. Moskowitz is often cited by papers focused on Lymphoma Diagnosis and Treatment (157 papers), Cutaneous lymphoproliferative disorders research (53 papers) and CAR-T cell therapy research (42 papers). Alison J. Moskowitz collaborates with scholars based in United States, Italy and France. Alison J. Moskowitz's co-authors include Steven M. Horwitz, Patricia L. Myskowski, Christiane Querfeld, Craig H. Moskowitz, Sarah I. Jawed, Sarah McCue Horwitz, Andrew D. Zelenetz, Joachim Yahalom, Matthew A. Lunning and Steven Horwitz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Alison J. Moskowitz

173 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alison J. Moskowitz United States	31	3.0k	2.1k	1.3k	1.1k	897	194	4.1k
Eva Geissinger Germany	27	1.2k 0.4×	874 0.4×	576 0.4×	653 0.6×	150 0.2×	79	2.3k
Ingrid Simonitsch‐Klupp Austria	29	1.1k 0.4×	586 0.3×	281 0.2×	816 0.8×	248 0.3×	93	2.4k
Roberto Giardini Italy	32	1.7k 0.6×	1.2k 0.6×	210 0.2×	339 0.3×	569 0.6×	84	3.2k
Sergej Konoplev United States	35	964 0.3×	1.4k 0.7×	282 0.2×	1.1k 1.0×	183 0.2×	154	4.6k
Giulio Fraternali Orcioni Italy	21	909 0.3×	643 0.3×	363 0.3×	427 0.4×	225 0.3×	81	1.9k
Sunil Reddy United States	24	704 0.2×	1.1k 0.5×	822 0.6×	746 0.7×	104 0.1×	72	2.7k
Aliakbar Shahsafaei United States	32	834 0.3×	898 0.4×	244 0.2×	1.0k 1.0×	220 0.2×	60	2.6k
Arjan Diepstra Netherlands	36	1.7k 0.6×	1.5k 0.7×	90 0.1×	1.3k 1.2×	279 0.3×	161	3.6k
Raymond E. Felgar United States	22	891 0.3×	486 0.2×	378 0.3×	1.4k 1.3×	159 0.2×	38	2.8k
Alberto Zamò Italy	25	1.0k 0.3×	1.1k 0.5×	164 0.1×	769 0.7×	173 0.2×	90	3.1k

Countries citing papers authored by Alison J. Moskowitz

Since Specialization

Citations

This map shows the geographic impact of Alison J. Moskowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison J. Moskowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison J. Moskowitz more than expected).

Fields of papers citing papers by Alison J. Moskowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison J. Moskowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison J. Moskowitz. The network helps show where Alison J. Moskowitz may publish in the future.

Co-authorship network of co-authors of Alison J. Moskowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Alison J. Moskowitz. A scholar is included among the top collaborators of Alison J. Moskowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison J. Moskowitz. Alison J. Moskowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Gunjan L., Tomalika R. Ullah, MM Hafeez, et al.. (2025). Infusional N-Acetylcysteine Enhances CAR T Cell Persistence in Patients with Aggressive B-Cell Lymphomas. Transplantation and Cellular Therapy. 31(2). S238–S239.

Moy, Andrea P., Stephen W. Dusza, Alison J. Moskowitz, et al.. (2025). Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series. The Oncologist. 30(9). 2 indexed citations

Abramson, Jeremy S., et al.. (2024). Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma. Critical Reviews in Oncology/Hematology. 204. 104499–104499.

Moskowitz, Alison J., Robert Stuver, & Steven M. Horwitz. (2024). Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs). Blood. 144(18). 1887–1897. 7 indexed citations

Zinzani, Pier Luigi, Gilles Salles, Alison J. Moskowitz, et al.. (2024). Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood Advances. 8(10). 2400–2404. 4 indexed citations

Stuver, Robert, Ting Zhou, Michael Zaidinski, et al.. (2024). A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia. Genes Chromosomes and Cancer. 63(6). e23252–e23252.

Herrera, Alex F., Pier Luigi Zinzani, Ann S. LaCasce, et al.. (2024). Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis. Blood Advances. 8(11). 2740–2752. 3 indexed citations

Ghione, Paola, Erel Joffe, M. Lia Palomba, et al.. (2024). CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas. PubMed. 1(4). 100031–100031. 1 indexed citations

Maakaron, Joseph, Dipenkumar Modi, Matthew Mei, et al.. (2024). Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study. Blood. 144(Supplement 1). 3052–3052. 2 indexed citations

10.

Smith, Alexandra N., Matthew J. Maurer, Julie Teruya‐Feldstein, et al.. (2024). Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood Advances. 8(9). 2172–2181. 2 indexed citations

11.

Zwezerijnen, Gerben J.C., Heiko Schöder, Marie José Kersten, et al.. (2023). Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma. Blood Advances. 7(21). 6732–6743. 10 indexed citations

12.

Stuver, Robert & Alison J. Moskowitz. (2023). Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma. Cancers. 15(3). 589–589. 9 indexed citations

13.

Kumar, Anita, Carla Casulo, Erel Joffe, et al.. (2022). Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. Leukemia & lymphoma. 63(12). 2889–2896. 1 indexed citations

14.

Porcu, Pierluigi, Stacie Hudgens, Sarah McCue Horwitz, et al.. (2020). Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(2). 97–105. 20 indexed citations

15.

Foss, Francine M., Steven M. Horwitz, Monica Civallero, et al.. (2019). Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. American Journal of Hematology. 95(2). 151–155. 38 indexed citations

16.

Querfeld, Christiane, Samantha Leung, Patricia L. Myskowski, et al.. (2018). Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer Immunology Research. 6(8). 900–909. 74 indexed citations

17.

Bellei, Monica, Francine M. Foss, Andrei R. Shustov, et al.. (2018). The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 103(7). 1191–1197. 88 indexed citations

18.

Herrera, Alex F., Alison J. Moskowitz, Nancy L. Bartlett, et al.. (2017). Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 131(11). 1183–1194. 230 indexed citations

19.

Schöder, Heiko, Andrew D. Zelenetz, Paul A. Hamlin, et al.. (2015). Prospective Study of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma. Journal of Nuclear Medicine. 57(5). 728–734. 30 indexed citations

20.

Moskowitz, Alison J., Matthew A. Lunning, & Steven M. Horwitz. (2014). How I treat the peripheral T-cell lymphomas. Blood. 123(17). 2636–2644. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact